{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T02:44:34Z","timestamp":1772765074690,"version":"3.50.1"},"reference-count":93,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Research in Translational Medicine"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.retram.2025.103499","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:15:12Z","timestamp":1738628112000},"page":"103499","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Post-transplant cyclophosphamide in matched donor transplantation: are we there yet?"],"prefix":"10.1016","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0844-0708","authenticated-orcid":false,"given":"Lorenzo","family":"Lazzari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gloria","family":"Catalano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Sannipoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Teresa","family":"Lupo-Stanghellini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacopo","family":"Peccatori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Ciceri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6117-5328","authenticated-orcid":false,"given":"Raffaella","family":"Greco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.retram.2025.103499_bib0001","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/s41409-022-01691-w","article-title":"Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022","volume":"57","author":"Snowden","year":"2022","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.retram.2025.103499_bib0002","first-page":"1","article-title":"Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years","author":"Passweg","year":"2021","journal-title":"Bone Marrow Transpl"},{"issue":"6","key":"10.1016\/j.retram.2025.103499_bib0003","first-page":"2062","article-title":"Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors","volume":"96","author":"Nash","year":"2000","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.retram.2025.103499_bib0004","first-page":"2303","article-title":"Phase III study comparing methotrexate and tacrolimus (Prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation","volume":"92","author":"Ratanatharathorn","year":"1998","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.retram.2025.103499_bib0005","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1056\/NEJM198603203141201","article-title":"Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia","volume":"314","author":"Storb","year":"2009","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.retram.2025.103499_bib0006","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/sj.bmt.1704647","article-title":"A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation","volume":"34","author":"Bolwell","year":"2004","journal-title":"Bone Marrow Transpl"},{"issue":"7","key":"10.1016\/j.retram.2025.103499_bib0007","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1182\/blood-2006-09-046219","article-title":"Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation","volume":"109","author":"Cutler","year":"2007","journal-title":"Blood"},{"issue":"4873","key":"10.1016\/j.retram.2025.103499_bib0008","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1126\/science.3262237","article-title":"Effects of cyclosporine A on T cell development and clonal deletion","volume":"241","author":"Jenkins","year":"1988","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.retram.2025.103499_bib0009","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1182\/blood.V77.7.1423.1423","article-title":"Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia","volume":"77","author":"Bacigalupo","year":"1991","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.retram.2025.103499_bib0010","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/s41409-020-0792-x","article-title":"Rabbit ATG\/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel","volume":"55","author":"Bonifazi","year":"2020","journal-title":"Bone Marrow Transpl"},{"issue":"8","key":"10.1016\/j.retram.2025.103499_bib0011","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1080\/10428194.2016.1266624","article-title":"Efficacy of antithymocyte globulin for allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis","volume":"58","author":"Arai","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.retram.2025.103499_bib0012","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/s41409-017-0043-y","volume":"53","author":"Devillier","year":"2018","journal-title":"Bone Marrow Transpl"},{"issue":"4","key":"10.1016\/j.retram.2025.103499_bib0013","doi-asserted-by":"crossref","first-page":"E368","DOI":"10.1111\/ctr.12131","article-title":"A high antithymocyte globulin dose increases the risk of relapse after reduced intensity conditioning HSCT with unrelated donors","volume":"27","author":"Remberger","year":"2013","journal-title":"Clin Transplant"},{"issue":"6","key":"10.1016\/j.retram.2025.103499_bib0014","article-title":"Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults","volume":"2023","author":"Chakupurakal","year":"2023","journal-title":"Cochran Datab Systemat Rev"},{"issue":"12","key":"10.1016\/j.retram.2025.103499_bib0015","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1182\/blood.V98.12.3456","article-title":"Durable engraftment of major histocompatibility complex\u2013incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide","volume":"98","author":"Luznik","year":"2001","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.retram.2025.103499_bib0016","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.retram.2025.103499_bib0017","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1053\/bbmt.2002.v8.pm12171484","article-title":"Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide","volume":"8","author":"O'Donnell","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"10.1016\/j.retram.2025.103499_bib0018","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1182\/blood-2015-04-639831","article-title":"Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia","volume":"126","author":"Ciurea","year":"2015","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.retram.2025.103499_bib0019","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.4049\/jimmunol.145.5.1303","article-title":"Sequential mechanisms of cyclophosphamide-induced skin allograft tolerance including the intrathymic clonal deletion followed by late breakdown of the clonal deletion","volume":"145","author":"Eto","year":"1990","journal-title":"J Immunol"},{"issue":"13","key":"10.1016\/j.retram.2025.103499_bib0020","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1182\/blood-2013-10-525873","article-title":"Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice","volume":"124","author":"Ganguly","year":"2014","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.retram.2025.103499_bib0021","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1182\/bloodadvances.2022007026","article-title":"Posttransplantation cyclophosphamide expands functional myeloid-derived suppressor cells and indirectly influences Tregs","volume":"7","author":"Fletcher","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.retram.2025.103499_bib0022","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02668","article-title":"Mechanisms of graft-versus-host disease prevention by post-transplantation cyclophosphamide: an evolving understanding","volume":"10","author":"Nunes","year":"2019","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.retram.2025.103499_bib0023","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1172\/JCI124218","article-title":"Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression","volume":"129","author":"Wachsmuth","year":"2019","journal-title":"J Clin Invest"},{"issue":"11","key":"10.1016\/j.retram.2025.103499_bib0024","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nrclinonc.2009.146","article-title":"Cyclophosphamide and cancer: golden anniversary","volume":"6","author":"Emadi","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"10.1016\/j.retram.2025.103499_bib0025","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1200\/JCO.21.02293","article-title":"Randomized phase III BMT CTN Trial of calcineurin inhibitor-free chronic graft-versus-host disease interventions in myeloablative hematopoietic cell transplantation for hematologic malignancies","volume":"40","author":"Luznik","year":"2022","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.retram.2025.103499_bib0026","doi-asserted-by":"crossref","first-page":"695.e1","DOI":"10.1016\/j.jtct.2022.07.021","article-title":"Post-transplantation cyclophosphamide versus tacrolimus and methotrexate graft-versus-host disease prophylaxis for HLA-matched donor transplantation","volume":"28","author":"Mehta","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.retram.2025.103499_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2023.101092","article-title":"Does PTCY increase the risk of infections?","volume":"62","author":"Mikulska","year":"2023","journal-title":"Blood Rev"},{"issue":"4","key":"10.1016\/j.retram.2025.103499_bib0028","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/s41409-020-01092-x","article-title":"Patterns of infection and infectious-related mortality in patients receiving post-transplant high dose cyclophosphamide as graft-versus-host-disease prophylaxis: impact of HLA donor matching","volume":"56","author":"Irene","year":"2020","journal-title":"Bone Marrow Transpl"},{"issue":"23","key":"10.1016\/j.retram.2025.103499_bib0029","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1182\/blood.2020009362","article-title":"Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis","volume":"137","author":"Goldsmith","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.retram.2025.103499_bib0030","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/bjh.17563","article-title":"Incidence and impact of community respiratory viral infections in post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis and haploidentical stem cell transplantation","volume":"194","author":"Mulroney","year":"2021","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.retram.2025.103499_bib0031","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1182\/bloodadvances.2022009112","article-title":"Impact of GVHD prophylaxis on CMV reactivation and disease after HLA-matched peripheral blood stem cell transplantation","volume":"7","author":"Oshima","year":"2023","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.retram.2025.103499_bib0032","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.bbmt.2020.01.013","article-title":"Infections after allogenic transplant with post-transplant cyclophosphamide: impact of donor HLA matching","volume":"26","author":"Oltolini","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"18","key":"10.1016\/j.retram.2025.103499_bib0033","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/bloodadvances.2022009274","article-title":"Human herpesvirus 6\u2013specific T-cell immunity in allogeneic hematopoietic stem cell transplant recipients","volume":"7","author":"Noviello","year":"2023","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.retram.2025.103499_bib0034","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.3324\/haematol.2022.280685","article-title":"Cytomegalovirus-specific T cells restricted for shared and donor human leukocyte antigens differentially impact on cytomegalovirus reactivation risk after allogeneic hematopoietic stem cell transplantation","volume":"108","author":"Tassi","year":"2023","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.retram.2025.103499_bib0035","doi-asserted-by":"crossref","first-page":"850.e1","DOI":"10.1016\/j.jtct.2022.09.001","article-title":"Bacterial bloodstream infections in patients undergoing allogeneic hematopoietic cell transplantation with post-transplantation cyclophosphamide","volume":"28","author":"Salas","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"9","key":"10.1016\/j.retram.2025.103499_bib0036","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1182\/bloodadvances.2022008226","article-title":"Levofloxacin prophylaxis vs no prophylaxis in patients with neutropenia within an endemic country for carbapenem-resistant GNB","volume":"7","author":"Clerici","year":"2023","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.retram.2025.103499_bib0037","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s11684-018-0641-0","article-title":"Clinical risk score for invasive fungal diseases in patients with hematological malignancies undergoing chemotherapy: China Assessment of Antifungal Therapy in Hematological Diseases (CAESAR) study","volume":"13","author":"Wang","year":"2019","journal-title":"Front Med"},{"issue":"1","key":"10.1016\/j.retram.2025.103499_bib0038","doi-asserted-by":"crossref","first-page":"114.e1","DOI":"10.1016\/j.jtct.2023.09.017","article-title":"Incidence and impact of fungal infections in post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis and haploidentical hematopoietic cell transplantation: a center for international blood and marrow transplant research analysis","volume":"30","author":"Papanicolaou","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.retram.2025.103499_bib0039","doi-asserted-by":"crossref","first-page":"857","DOI":"10.3324\/haematol.2020.271445","article-title":"Comparison of immune reconstitution between anti-T-lymphocyte globulin and posttransplant cyclophosphamide as acute graft-versus-host disease prophylaxis in allogeneic myeloablative peripheral blood stem cell transplantation","volume":"107","author":"Massoud","year":"2022","journal-title":"Haematologica"},{"issue":"Supplement 1","key":"10.1016\/j.retram.2025.103499_bib0040","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1182\/blood-2023-188032","article-title":"Large-scale post-transplant TCR deep sequencing reveals a major T cell diversity bottleneck with post-transplant cyclophosphamide with implications for both efficacy and toxicity: results of the BMT CTN 1801 study","volume":"142","author":"Kean","year":"2023","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.retram.2025.103499_bib0041","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1182\/blood-2009-11-251595","article-title":"High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease","volume":"115","author":"Luznik","year":"2010","journal-title":"Blood"},{"issue":"31","key":"10.1016\/j.retram.2025.103499_bib0042","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1200\/JCO.2013.54.0625","article-title":"Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning","volume":"32","author":"Kanakry","year":"2014","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.retram.2025.103499_bib0043","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1182\/blood-2014-07-587477","article-title":"Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS","volume":"124","author":"Kanakry","year":"2014","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.retram.2025.103499_bib0044","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.bbmt.2011.02.002","volume":"17","author":"Devine","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"26","key":"10.1016\/j.retram.2025.103499_bib0045","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2012.41.7071","volume":"30","author":"Pasquini","year":"2012","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.retram.2025.103499_bib0046","doi-asserted-by":"crossref","first-page":"6375","DOI":"10.1182\/blood-2011-01-329821","article-title":"Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius","volume":"117","author":"Soci\u00e9","year":"2011","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.retram.2025.103499_bib0047","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S1470-2045(09)70225-6","article-title":"Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial","volume":"10","author":"Finke","year":"2009","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.retram.2025.103499_bib0048","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.bbmt.2015.01.026","article-title":"Phase II trial of graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide after reduced-intensity busulfan\/fludarabine conditioning for hematological malignancies","volume":"21","author":"Alousi","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.retram.2025.103499_bib0049","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/ejh.12541","article-title":"OCTET-CY: A phase II study to investigate the efficacy of post-transplant cyclophosphamide as sole graft-versus-host prophylaxis after allogeneic peripheral blood stem cell transplantation","volume":"96","author":"Holtick","year":"2016","journal-title":"Eur J Haematol"},{"issue":"5","key":"10.1016\/j.retram.2025.103499_bib0050","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.bbmt.2015.01.020","article-title":"Single-agent high-dose cyclophosphamide for graft-versus-host disease prophylaxis in human leukocyte antigen-matched reduced-intensity peripheral blood stem cell transplantation results in an unacceptably high rate of severe acute graft-versus-host disease","volume":"21","author":"Bradstock","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.retram.2025.103499_bib0051","doi-asserted-by":"crossref","first-page":"e1242","DOI":"10.1002\/ctm2.1242","article-title":"Post-transplant cyclophosphamide as sole GHVD prophylaxis after matched reduced-intensity conditioning allotransplant","volume":"13","author":"Le Bourgeois","year":"2023","journal-title":"Clin Transl Med"},{"issue":"11","key":"10.1016\/j.retram.2025.103499_bib0052","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1182\/blood-2015-10-672071","article-title":"Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation","volume":"127","author":"Mielcarek","year":"2016","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.retram.2025.103499_bib0053","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.bbmt.2016.03.004","article-title":"Graft-versus-host disease prophylaxis in unrelated peripheral blood stem cell transplantation with post-transplantation cyclophosphamide, tacrolimus, and mycophenolate mofetil","volume":"22","author":"Moiseev","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.retram.2025.103499_bib0054","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.bbmt.2016.12.636","article-title":"Post-transplant cyclophosphamide and tacrolimus-mycophenolate mofetil combination prevents graft-versus-host disease in allogeneic peripheral blood hematopoietic cell transplantation from HLA-matched donors","volume":"23","author":"Carnevale-Schianca","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.retram.2025.103499_bib0055","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1016\/j.bbmt.2014.07.020","article-title":"Calcineurin inhibitor\u2013free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation","volume":"20","author":"Solomon","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.retram.2025.103499_bib0056","doi-asserted-by":"crossref","first-page":"776.e1","DOI":"10.1016\/j.jtct.2021.05.023","article-title":"Posttransplantation cyclophosphamide- and sirolimus-based graft-versus-host-disease prophylaxis in allogeneic stem cell transplant","volume":"27","author":"Greco","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"10.1016\/j.retram.2025.103499_bib0057","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/s41409-019-0771-2","article-title":"Incorporating posttransplant cyclophosphamide-based prophylaxis as standard-of-care outside the haploidentical setting: challenges and review of the literature","volume":"55","author":"Garc\u00eda-Cadenas","year":"2020","journal-title":"Bone Marrow Transpl"},{"issue":"4","key":"10.1016\/j.retram.2025.103499_bib0058","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s41409-018-0367-2","article-title":"Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10\/10 HLA-matched unrelated donor hematopoietic stem cell transplantation","volume":"54","author":"Shah","year":"2019","journal-title":"Bone Marrow Transpl"},{"issue":"27","key":"10.1016\/j.retram.2025.103499_bib0059","doi-asserted-by":"crossref","first-page":"4570","DOI":"10.1200\/JCO.2008.20.9692","article-title":"Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia","volume":"27","author":"Ringd\u00e9n","year":"2009","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.retram.2025.103499_bib0060","doi-asserted-by":"crossref","first-page":"489.e1","DOI":"10.1016\/j.jtct.2022.05.009","article-title":"PTCY and tacrolimus for GVHD prevention for older adults undergoing HLA-matched sibling and unrelated donor AlloHCT","volume":"28","author":"Salas","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.retram.2025.103499_bib0061","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-018-0586-4","article-title":"Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT","volume":"11","author":"Ruggeri","year":"2018","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.retram.2025.103499_bib0062","article-title":"Post-transplant cyclophosphamide with Sirolimus or Cyclosporine for GvHD prophylaxis in matched related and unrelated transplantation: a two-center analysis on 213 consecutive patients","author":"Piemontese","year":"2024595692","journal-title":"Bone Marrow Transpl"},{"issue":"21","key":"10.1016\/j.retram.2025.103499_bib0063","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1182\/bloodadvances.2019000236","article-title":"Posttransplant cyclophosphamide vs cyclosporin A and methotrexate as GVHD prophylaxis in matched sibling transplantation","volume":"3","author":"Kwon","year":"2019","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.retram.2025.103499_bib0064","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/s41409-023-02033-0","volume":"58","author":"Dachy","year":"2023","journal-title":"Bone Marrow Transpl"},{"issue":"Supplement 1","key":"10.1016\/j.retram.2025.103499_bib0065","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1182\/blood-2023-174821","volume":"142","author":"Nagler","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.retram.2025.103499_bib0066","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1016\/j.jtct.2023.12.080","volume":"30","author":"Nagler","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.retram.2025.103499_bib0067","doi-asserted-by":"crossref","first-page":"213.e1","DOI":"10.1016\/j.jtct.2023.11.020","article-title":"Post-transplantation cyclophosphamide and tacrolimus for graft-versus-host disease prevention after allogeneic hematopoietic cell transplantation from HLA-matched donors has more advantages than limitations","volume":"30","author":"Salas","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"10.1016\/j.retram.2025.103499_bib0068","doi-asserted-by":"crossref","first-page":"86.e1","DOI":"10.1016\/j.jtct.2021.11.013","article-title":"Graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide versus cyclosporine a and methotrexate in matched sibling donor transplantation","volume":"28","author":"Nagler","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.retram.2025.103499_bib0069","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-020-00923-0","article-title":"Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10\/10 HLA-matched unrelated donors","volume":"13","author":"Brissot","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.retram.2025.103499_bib0070","author":"Salas","year":"2024594479","journal-title":"Bone Marrow Transpl"},{"issue":"2","key":"10.1016\/j.retram.2025.103499_bib0071","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/cncr.33255","volume":"127","author":"Battipaglia","year":"2021","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.retram.2025.103499_bib0072","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1016\/S2352-3026(18)30221-7","volume":"6","author":"Bola\u00f1os-Meade","year":"2019","journal-title":"Lancet Haematol"},{"issue":"25","key":"10.1016\/j.retram.2025.103499_bib0073","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.retram.2025.103499_bib0074","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1182\/bloodadvances.2021005847","article-title":"Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial","volume":"6","author":"Broers","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.retram.2025.103499_bib0075","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41408-024-00990-3","volume":"14","author":"Brissot","year":"2024","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.retram.2025.103499_bib0076","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1016\/S2352-3026(19)30256-X","article-title":"Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation","volume":"7","author":"Penack","year":"2020","journal-title":"Lancet Haematol"},{"issue":"6","key":"10.1016\/j.retram.2025.103499_bib0077","doi-asserted-by":"crossref","first-page":"e293","DOI":"10.1016\/S2352-3026(17)30081-9","article-title":"Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial","volume":"4","author":"Finke","year":"2017","journal-title":"Lancet Haematol"},{"issue":"9","key":"10.1016\/j.retram.2025.103499_bib0078","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S1470-2045(09)70225-6","article-title":"Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial","volume":"10","author":"Finke","year":"2009","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.retram.2025.103499_bib0079","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1016\/S2352-3026(19)30220-0","volume":"7","author":"Walker","year":"2020","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.retram.2025.103499_bib0080","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1056\/NEJMoa1506002","article-title":"Antilymphocyte globulin for prevention of chronic graft-versus-host disease","volume":"374","author":"Kr\u00f6ger","year":"2016","journal-title":"N Engl J Med"},{"issue":"36","key":"10.1016\/j.retram.2025.103499_bib0081","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1200\/JCO.2017.75.8177","article-title":"Prospective, randomized, double-blind, phase iii clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation","volume":"35","author":"Soiffer","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.retram.2025.103499_bib0082","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1016\/S2352-3026(19)30256-X","article-title":"Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation","volume":"7","author":"Penack","year":"2020","journal-title":"Lancet Haematol"},{"issue":"25","key":"10.1016\/j.retram.2025.103499_bib0083","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"},{"issue":"S7","key":"10.1016\/j.retram.2025.103499_bib0084","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/imj.15588","article-title":"Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2021","volume":"51","author":"Teh","year":"2021","journal-title":"Intern Med J"},{"issue":"3","key":"10.1016\/j.retram.2025.103499_bib0085","doi-asserted-by":"crossref","first-page":"E846","DOI":"10.1097\/HS9.0000000000000846","article-title":"Prediction of nonrelapse mortality in patients with acute myeloid leukemia and acute lymphoblastic leukemia receiving allogeneic stem cell transplantation with posttransplantation cyclophosphamide-based graft versus host disease prophylaxis","volume":"7","author":"Hermans","year":"2023","journal-title":"Hemasphere"},{"issue":"4","key":"10.1016\/j.retram.2025.103499_bib0086","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41409-022-01908-y","article-title":"Reduced post-transplant cyclophosphamide doses in haploidentical hematopoietic cell transplantation for elderly patients with hematological malignancies","volume":"58","author":"Dul\u00e9ry","year":"2023","journal-title":"Bone Marrow Transpl"},{"issue":"3","key":"10.1016\/j.retram.2025.103499_bib0087","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/s41409-020-01065-0","article-title":"Reduced dose of posttransplant cyclophosphamide in HLA-haploidentical peripheral blood stem cell transplantation","volume":"56","author":"Sugita","year":"2021","journal-title":"Bone Marrow Transpl"},{"issue":"Supplement 1","key":"10.1016\/j.retram.2025.103499_bib0088","doi-asserted-by":"crossref","first-page":"4872","DOI":"10.1182\/blood-2021-153455","article-title":"De-escalation of PTCy dosing in matched allogenic transplants: a single institution retrospective study","volume":"138","author":"Ackula","year":"2021","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.retram.2025.103499_bib0089","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1080\/10428194.2021.1966781","article-title":"Lower dose of ATG combined with post-transplant cyclophosphamide for HLA matched RIC alloHCT is associated with effective control of GVHD and less viral infections","volume":"62","author":"Salas","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"10.1016\/j.retram.2025.103499_bib0090","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1038\/s41409-020-0813-9","article-title":"Dual T-cell depletion with ATG and PTCy for peripheral blood reduced intensity conditioning allo-HSCT results in very low rates of GVHD","volume":"55","author":"Salas","year":"2020","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.retram.2025.103499_bib0091","article-title":"Post-transplantation cyclophosphamide, tacrolimus and low-dose ATG as GVHD prophylaxis for allogeneic peripheral stem cell transplantation for adult patients with lymphoid malignancies: a single arm phase II study","volume":"8","author":"Jiang","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"10.1016\/j.retram.2025.103499_bib0092","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11041106","article-title":"Addition of a single low dose of anti T-lymphocyte globulin to post-transplant cyclophosphamide after allogeneic hematopoietic stem cell transplant: a pilot study","volume":"11","author":"Xue","year":"2022","journal-title":"J Clin Med"},{"issue":"2","key":"10.1016\/j.retram.2025.103499_bib0093","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1159\/000506758","article-title":"A prospective pilot study of graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and ruxolitinib in patients with myelofibrosis","volume":"144","author":"Morozova","year":"2021","journal-title":"Acta Haematol"}],"container-title":["Current Research in Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S245231862500008X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S245231862500008X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T16:54:21Z","timestamp":1748451261000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S245231862500008X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":93,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S245231862500008X"],"URL":"https:\/\/doi.org\/10.1016\/j.retram.2025.103499","relation":{},"ISSN":["2452-3186"],"issn-type":[{"value":"2452-3186","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Post-transplant cyclophosphamide in matched donor transplantation: are we there yet?","name":"articletitle","label":"Article Title"},{"value":"Current Research in Translational Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.retram.2025.103499","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"103499"}}